University of Wisconsin–Madison

Author: crauwerdink

Mixed Dementia, Explained

Though brain and cognitive changes are typically diagnosed as one form of dementia, recent studies have shown that mixed dementia is more common than previously thought. Mixed dementia, also known as Multiple-etiology dementia, is a condition where brain changes are caused by more than one neurological disease, such as Alzheimer’s disease, Lewy body dementia (LBD), or frontotemporal dementia. Dr. Roderick Corriveau joins the podcast to discuss what is known about mixed dementia and how the field of studying neurological diseases is advancing to diagnose and treat this condition. Guest: Roderick Corriveau, PhD, program director, National Institute of Neurological Disorders and Stroke (NINDS), NIH Lead, Alzheimer’s Disease-Related Dementias (ADRD) Summits

The Case for Disclosing Biomarker Results to Alzheimer’s Research Participants

Though several validated biomarkers are studied and used in Alzheimer’s disease research, most research participants don’t have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it's as important for the field to study biomarker disclosures as it is to study the biomarkers themselves. Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania

Promoting Open Science and Community Engagement with the National Institute on Aging

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 6 Concluding our special series on the 2022 Spring ADRC Meeting, Dr. Cerise Elliott joins the podcast to discuss the NIA’s work within the field of Alzheimer’s disease research, how the NIA promotes open science to advance research across the ADRC program, and other key takeaways from the spring meeting. Guest: Cerise Elliott, PhD, program director for clinical interventions and diagnostics, division of neuroscience, National Institute on Aging

Moving into the Digital Era of Alzheimer’s Disease Research

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 5 Whether it be due to new research findings, innovative approaches and ideas, or technological advancements, Alzheimer’s disease research is constantly evolving. Now, dementia research is headed into the digital frontier. Dr. Rhoda Au joins the podcast to discuss digital biomarkers, gamifying cognitive testing, and how the field of Alzheimer’s disease research is entering its digital age. Guest: Rhoda Au, PhD, digital technology leader, Boston University Alzheimer’s Disease Research Center, co-principal investigator, director of neuropsychology, Framingham Heart Study, professor, Boston University School of Medicine

Protecting Participant Privacy and Making Predictions Using Alzheimer’s Data

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 3 With big data comes big responsibility. Dr. Sean Mooney joins the podcast to discuss his work with NACC, the precautions NACC takes to keep participant data secure, and how this data can be used to better predict Alzheimer’s disease risk to allow for earlier interventions. Guest: Sean Mooney, PhD, associate director of technology, National Alzheimer’s Coordinating Center, Chief Research Information Officer, UW Medicine, professor, University of Washington

The Future of Sharing and Accessing Alzheimer’s Disease Data

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 2 Dr. Sarah Biber, the program director for NACC, joins the podcast to discuss building a one-stop shop for Alzheimer’s Disease Research Center (ADRC) data and what it means for the future of collaborative Alzheimer’s disease research. Guest: Sarah Biber, PhD, program director, National Alzheimer’s Coordinating Center

Introducing the National Alzheimer’s Coordinating Center

Dementia Matters Special Series: The National Strategy for Alzheimer's Disease Data and Research Part 1: Kicking off our six-episode series on the National Alzheimer’s Coordinating Center and their Spring 2022 ADRC meeting, Dr. Walter Kukull joins the podcast. He explains what NACC is, what they do with the data they collect from the 42+ Alzheimer’s Disease Research Centers, the center’s biannual ADRC meetings and what he’s most excited about for the next five years of Alzheimer’s disease research. Guest: Walter Kukull, PhD, director, National Alzheimer’s Coordinating Center, professor, University of Washington department of epidemiology

Improving Registries and Representation in Alzheimer’s Disease Research

Research participants are recruited through a variety of practices. One of the most popular tools are registries, but how can registries affect diversity and representation within research? Josh Grill joins the podcast to discuss his work studying research registries, their effects on representation for disadvantaged communities, and how research recruitment and outreach can be improved going forward. Guest: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine

Highlights from the 2022 Alzheimer’s Association International Conference

AAIC Special Series Part 8: Closing out our special series spotlighting the 2022 Alzheimer’s Association International Conference, Dr. Percy Griffin joins the podcast to discuss highlights from this year’s event. Guest: Percy Griffin, PhD, director, scientific engagement, Alzheimer’s Association

COVID-19 and Its Effects on the Brain

AAIC Special Series Part 7: Recent studies have shown that 1 in 5 U.S. adults who were diagnosed with COVID-19 now deal with Long COVID, a condition where individuals report fatigue, cognitive issues, difficulty breathing, and other symptoms lasting at least three months after infection. With these reported effects on cognition and brain health, what else do we know about COVID’s impact on the brain? Dr. Heather Snyder joins us to talk about what we know about COVID-19’s effects on the brain and her upcoming scientific session at AAIC 2022. Guest: Heather Snyder, PhD, vice president, medical & scientific relations, Alzheimer’s Association

Apathy and Alzheimer’s Disease: Plenary Preview with Dr. Krista Lanctôt

AAIC Special Series Part 6: Dr. Krista Lanctôt joins the podcast to discuss apathy, how it develops in people with Alzheimer’s disease, and her upcoming AAIC 2022 plenary talk. Guest: Krista Lanctôt, PhD, senior scientist, Sunnybrook Health Sciences Centre, full professor, University of Toronto

Scientific Importance of Diversity in Alzheimer’s Disease Research

AAIC Special Series Part 5: Bringing together scientists, clinicians, and research participants from all over the world, AAIC 2022 showcases the work and experiences of people from unique backgrounds and perspectives and highlights the importance of diversity in Alzheimer’s disease research. Dr. Carl Hill joins the podcast to discuss why diversity is important in scientific research and how AAIC 2022 supports efforts to make Alzheimer’s disease research more equitable and inclusive. Guest: Carl Hill, PhD, MPH, chief diversity, equity and inclusion officer, Alzheimer’s Association

Delirium and Dementia: Plenary Preview with Dr. Sharon Inouye

AAIC Special Series Part 4: Research into delirium, a condition where older adults experience acute confusional states during hospitalizations, and its connections to dementia have led to  numerous advancements in hospital care and treatments. Dr. Sharon Inouye joins the podcast to discuss how our understanding of delirium has changed over the past 30 years and previews her upcoming AAIC plenary talk about the intersection of delirium and dementia. Guest: Sharon Inouye, PhD, director, Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, professor, Harvard Medical School

Non-Pharmacological Care for People with MCI and Dementia: Plenary Preview with Dr. Linda Lam

AAIC Special Series Part 3: Mild cognitive impairment (MCI) is an early stage of memory loss and cognitive impairment that can develop into dementia. While physicians have medications they can prescribe to manage the condition, many researchers and doctors are focusing on lifestyle interventions that could support a person’s cognition and address behavioral changes. Dr. Linda Lam joins the podcast to discuss her work studying mild cognitive impairment and preview her upcoming AAIC plenary talk on non-pharmacological treatments for MCI and dementia. Guest: Linda Lam, MBChB, MD, professor, Chinese University of Hong Kong

Opening Doors to Research Participants: Making Scientific Conferences Accessible to the Public

AAIC Special Series Part 2: Attending scientific conferences is usually a major commitment, often requiring attendees to travel, pay attendance fees, and take time out during the day to learn about groundbreaking research. Recent conferences like the Alzheimer’s Association International Conference (AAIC) are opening their doors virtually to make the events more accessible to research participants, care partners, and the general public. Sarah Walter joins the podcast as part of our special series previewing AAIC 2022 to discuss her article on how virtual scientific conferences impact research participant engagement and why it’s important for participants to hear about the research they’re involved in. Guest: Sarah Walter, MSc, program administrator, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, University of Southern California